QNTA got a Great follow-up Review @ InsiderFinancial and Investors/Traders Sentiments rising Exponentially @ Popular SM Platform MB's.
On May 11th, QNTA announced a shakeup in its management team. Philip Sands is stepping down from the role of President.
He is being replaced on an interim basis by Medolife CEO Dr. Arthur Mikaelian who will also serve as Chairman of the Board.
Even though it was a planned step in the merger process, the headline also shook up the investment community because it was perceived as a step in the right direction.
It sparked a strong volume run above $0.15 that could mean the previous peak of $0.20 is not far away.
So, while QNTA is widely perceived as a COVID-19 play, investors also get exposure to the oncology space.
In pre-clinical studies, Escozine in combination with chemotherapy was found to be effective in killing leukemia and lymphoma cancer cells.
Investors are hoping for good news from the FDA regarding the advancement of Escozine for COVID-19.
If the new leadership structure can deliver on this potential catalyst, QNTA is likely to explode.
In the meantime, momentum is in this stock’s favor.
